根治性放疗治疗合并特发性肺纤维化的非小细胞肺癌患者的初步结果:X线与质子治疗的比较
该回顾性研究分析了2010年1月至2017年10月间30例合并特发性肺纤维化(IPF)的I-II期非小细胞肺癌(NSCLC)患者,其中22例接受X线放疗、8例接受质子治疗。X线组治疗相关死亡4例(18.2%),质子组无治疗相关死亡;质子组1年总生存率66.7% vs X线组46.4%(p=0.081),在GAP II-III期亚组中质子组1年OS 50.0% vs X线组26.4%(p=0.036)。作者认为质子治疗可能有助于减少急性和致死性并发症。
要点
- 合并IPF的I-II期NSCLC根治性放疗后,X线组治疗相关死亡4例(18.2%),质子组0例。
- 质子组1年OS 66.7% vs X线组46.4%(p=0.081),差异未达统计学显著。
- GAP II-III期亚组中质子组1年OS 50.0% vs X线组26.4%(p=0.036),差异有统计学意义。
核心结论
- 放疗与合并IPF患者的严重治疗相关并发症相关。
- 质子治疗可能有助于减少这些急性和致死性并发症。
研究设计与样本
- 回顾性分析2010年1月至2017年10月接受根治性单纯放疗的264例I-II期NSCLC患者病历。
- 最终分析其中30例(11.4%)合并IPF的患者,X线放疗22例、质子放疗8例。
- 比较X线与质子治疗的治疗相关并发症和生存结局。
主要发现
- 中位随访11个月(范围2至51个月),所有存活患者随访至少9个月。
- 治疗相关死亡:X线组4例(18.2%),质子组0例。
- 多数患者在肺部症状出现后一个月内死亡,尽管接受了积极治疗。
- 1年OS率:X线组46.4% vs 质子组66.7%,质子组显示生存更好的趋势(p=0.081)。
- GAP II-III期亚组单因素分析中,质子组1年OS 50.0% vs X线组26.4%(p=0.036),质子组生存结局显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with fatal complications after radiotherapy (RT) for lung cancer patients; however, the role of proton therapy to reduce the incidence of life-threatening complications is unclear. Herein, we present the preliminary results of early-stage lung cancer patients having IPF and treated with RT, with a focus on the comparison between X-ray and proton therapy. METHODS: From January 2010 to October 2017, we retrospectively reviewed the medical records of 264 patients with stage I-II non-small cell lung cancer (NSCLC) treated with definitive RT alone. Ultimately, 30 patients (11.4%) who had underlying IPF were analyzed. Among these, X-ray and proton RT were delivered to 22 and 8 patients, respectively. Treatment-related complications and survival outcomes were compared between X-ray and proton therapy. RESULTS: The median follow-up duration was 11 months (range, 2 to 51 months). All living patients were followed-up at least 9 months. Treatment-related death occurred in four patients (18.2%) treated with X-ray but none with proton therapy. Most patients died within one month after the onset of pulmonary symptoms in spite of aggressive treatment. In addition, the 1-year overall survival (OS) rate in patients treated with X-ray and proton was 46.4 and 66.7%, respectively, and patients treated with proton therapy showed a tendency of better survival compared to X-ray (p = 0.081). Especially, in GAP stage II and III subgroups, patients treated with proton therapy showed significantly increased survival outcomes compared to X-ray (1-year OS rate; 50.0% versus 26.4%, p = 0.036) in univariate analysis. CONCLUSIONS: RT is associated with serious treatment-related complications in patients with IPF. Proton therapy may be helpful to reduce these acute and fatal complications. TRIAL REGISTRATION: retrospectively registered.
引用
- Kim H, Pyo H, Noh JM, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019. PMID: 30691496. doi:10.1186/s13014-019-1221-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。